Median overall survival (OS) was longer with modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) compared with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer, though the safety profiles were similar, according to a retrospective study presented at the ESMO World Congress on Gastrointestinal Cancer 2018.
Both mFOLFIRINOX and gemcitabine plus nab-paclitaxel are first-line options for the treatment of metastatic pancreatic cancer, but there are no conclusive data directly comparing these regimens. The goal of this study was to evaluate the safety and efficacy profiles of these regimens in patients with metastatic pancreatic cancer. Read more . . .